False negative bone scintigraphy in a patient with primary breast cancer: A possible transient phenomenon of bisphosphonate (alendronate) treatment

Demirkan B., Baskan Z., Alacacioglu A., Gorken İ., BEKİŞ R., Ada E., ...More

TUMORI, vol.91, no.1, pp.77-80, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 91 Issue: 1
  • Publication Date: 2005
  • Doi Number: 10.1177/030089160509100115
  • Journal Name: TUMORI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.77-80
  • Keywords: bisphosphonate, bone metastasis, breast cancer, 99mTc-MDP bone scan, WOMEN, PHARMACOKINETICS, DIPHOSPHONATE, METASTASES, TC-99M-MDP
  • Dokuz Eylül University Affiliated: Yes


Breast cancer is the most common cancer and the second leading cause of cancer deaths among women in developed countries. Bone is a frequent site of metastatic disease with a stage-dependent incidence. Most women with breast cancer are at risk of osteoporosis due to their age or their breast cancer treatment. Scintigraphy enables imaging of the entire skeleton with high sensitivity but limited specificity. The false positive rate varies from 1.6% to as high as 22%, while the false negative rate varies from 0.96% to 13%.